CAR T before the horse.

This review of CAR T-cells for refractory non-Hodgkin lymphoma is chock full of historical anecdotes and contemporary data. The uplifting conclusion is that it will become an even safer and more effective treatment alternative to stem cell transplant as its engineering and adjunct therapies continue to evolve. | Komanduri, J Clin Oncol 2021